Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aurinia Pharmaceuticals Inc AUPH

Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.


NDAQ:AUPH - Post by User

Bullboard Posts
Comment by Moneyday0on Aug 19, 2016 2:58pm
115 Views
Post# 25159530

RE:RE:Huge volume moves past days in US

RE:RE:Huge volume moves past days in USActually the they have permission and just need to review the next parameters with the FDA to ensure all parties are in agreement with what to measure and what constitutes a successful significant study. FDA is onboard all the way, are well aware of the deaths and results and everything I a go. Now more data over and above the 24 to 26 weeks ie: 30 weeks 36 weeks 48 weeks etc will provide more ammunition to the meeting to take place in October but things are well lined up.
Bullboard Posts